Key facts
- It has raised $2.7M; the latest was Seed Round ($2.7M) in Sep 2025.
- Notable investors include GrantConnect, Jumar Bioincubator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Celleo Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Celleo Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celleo Biotech
Developer of intelligent production systems designed to enable cell therapies to deliver population-level health outcomes. The company designs and develops various production systems for manufacturing cell and gene therapies that accommodate the diversity of processes, modalities and business models characteristic of the pre-clinical to clinical stage of therapies, enabling healthcare professionals to provide a new standard of personalized care.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2022
- Employees
- 23
- Website
- celleo.com/
- Ownership
- Privately Held (backing)
Celleo Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celleo Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celleo Biotech in its N-PORT filings yet. We sweep new filings monthly.